Patrizio Mattei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Patrizio Mattei has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Christoph Bieniossek
Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
5 shared publications- Daniel Kahne
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, USA
5 shared publications - Fabian Dey
Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
5 shared publications - Karanbir S. Pahil
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, USA
5 shared publications - Kenneth Bradley
Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
5 shared publications Thomas Clairfeuille
Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
5 shared publications
Latest Publications
- Open Access
- 11 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8022) , E17
Author Correction: A novel antibiotic class targeting the lipopolysaccharide transporter
- 11 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8022) , E17
Open AccessAuthor Correction: A novel antibiotic class targeting the lipopolysaccharide transporter
- Open Access
- 11 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8022) , E18
Author Correction: A new antibiotic traps lipopolysaccharide in its intermembrane transporter
- 11 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8022) , E18
Open AccessAuthor Correction: A new antibiotic traps lipopolysaccharide in its intermembrane transporter
- Open Access
- 10 January 2024
- Published by Springer Nature in Nature
- Vol. 625 (7996) , E27
Author Correction: A new antibiotic traps lipopolysaccharide in its intermembrane transporter
- 10 January 2024
- Published by Springer Nature in Nature
- Vol. 625 (7996) , E27
Open AccessAuthor Correction: A new antibiotic traps lipopolysaccharide in its intermembrane transporter
- Top Cited PapersOpen Access
- 3 January 2024
- Published by Springer Nature in Nature
- Vol. 625 (7995) , 566-571
A novel antibiotic class targeting the lipopolysaccharide transporter
Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global pathogen with limited treatment options1. No new antibiotic chemical class with activity against A. baumannii has reached patients in over 50 years1. Here we report the identification and optimization of tethered macrocyclic peptide (MCP) antibiotics with potent antibacterial activity against CRAB. The mechanism of action of this molecule class involves blocking the transport of bacterial lipopolysaccharide from the inner membrane to its destination on the outer membrane, through inhibition of the LptB2FGC complex. A clinical candidate derived from the MCP class, zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms. This chemical class represents a promising treatment paradigm for patients with invasive infections due to CRAB, for whom current treatment options are inadequate, and additionally identifies LptB2FGC as a tractable target for antimicrobial drug development.
- 3 January 2024
- Published by Springer Nature in Nature
- Vol. 625 (7995) , 566-571
Top Cited PapersOpen AccessA novel antibiotic class targeting the lipopolysaccharide transporter
Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global pathogen with limited treatment options1. No new antibiotic chemical class with activity against A. baumannii has reached patients in over 50 years1. Here we report the identification and optimization of tethered macrocyclic peptide (MCP) antibiotics with potent antibacterial activity against CRAB. The mechanism of action of this molecule class involves blocking the transport of bacterial lipopolysaccharide from the inner membrane to its destination on the outer membrane, through inhibition of the LptB2FGC complex. A clinical candidate derived from the MCP class, zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms. This chemical class represents a promising treatment paradigm for patients with invasive infections due to CRAB, for whom current treatment options are inadequate, and additionally identifies LptB2FGC as a tractable target for antimicrobial drug development.
- Top Cited PapersOpen Access
- 3 January 2024
- Published by Springer Nature in Nature
- Vol. 625 (7995) , 572-577
A new antibiotic traps lipopolysaccharide in its intermembrane transporter
Gram-negative bacteria are extraordinarily difficult to kill because their cytoplasmic membrane is surrounded by an outer membrane that blocks the entry of most antibiotics. The impenetrable nature of the outer membrane is due to the presence of a large, amphipathic glycolipid called lipopolysaccharide (LPS) in its outer leaflet1. Assembly of the outer membrane requires transport of LPS across a protein bridge that spans from the cytoplasmic membrane to the cell surface. Maintaining outer membrane integrity is essential for bacterial cell viability, and its disruption can increase susceptibility to other antibiotics2–6. Thus, inhibitors of the seven lipopolysaccharide transport (Lpt) proteins that form this transenvelope transporter have long been sought7–9. A new class of antibiotics that targets the LPS transport machine in Acinetobacter was recently identified. Here, using structural, biochemical and genetic approaches, we show that these antibiotics trap a substrate-bound conformation of the LPS transporter that stalls this machine. The inhibitors accomplish this by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate. Collectively, our findings identify an unusual mechanism of lipid transport inhibition, reveal a druggable conformation of the Lpt transporter and provide the foundation for extending this class of antibiotics to other Gram-negative pathogens.
- 3 January 2024
- Published by Springer Nature in Nature
- Vol. 625 (7995) , 572-577
Top Cited PapersOpen AccessA new antibiotic traps lipopolysaccharide in its intermembrane transporter
Gram-negative bacteria are extraordinarily difficult to kill because their cytoplasmic membrane is surrounded by an outer membrane that blocks the entry of most antibiotics. The impenetrable nature of the outer membrane is due to the presence of a large, amphipathic glycolipid called lipopolysaccharide (LPS) in its outer leaflet1. Assembly of the outer membrane requires transport of LPS across a protein bridge that spans from the cytoplasmic membrane to the cell surface. Maintaining outer membrane integrity is essential for bacterial cell viability, and its disruption can increase susceptibility to other antibiotics2–6. Thus, inhibitors of the seven lipopolysaccharide transport (Lpt) proteins that form this transenvelope transporter have long been sought7–9. A new class of antibiotics that targets the LPS transport machine in Acinetobacter was recently identified. Here, using structural, biochemical and genetic approaches, we show that these antibiotics trap a substrate-bound conformation of the LPS transporter that stalls this machine. The inhibitors accomplish this by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate. Collectively, our findings identify an unusual mechanism of lipid transport inhibition, reveal a druggable conformation of the Lpt transporter and provide the foundation for extending this class of antibiotics to other Gram-negative pathogens.